AMMAX BIO, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2020-03-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.ammaxbio.com
A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
Phase 2
Withdrawn
- Conditions
- IPF
- Interventions
- Biological: AMB-05XDrug: Placebo
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- AmMax Bio, Inc.
- Registration Number
- NCT05349760
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
Phase 2
Completed
- Conditions
- Pigmented Villonodular SynovitisTGCTTenosynovial Giant Cell Tumor
- Interventions
- Biological: AMB-05X
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- AmMax Bio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05349643
- Locations
- 🇳🇱
AmMax Bio, Clinical Site, Leiden, Netherlands
A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients
Phase 2
Terminated
- Conditions
- TGCTTenosynovial Giant Cell TumorPigmented Villonodular SynovitisPVNS - Pigmented Villonodular Synovitis
- Interventions
- Biological: AMB-05X
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- AmMax Bio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04938180
- Locations
- 🇺🇦
AmMax Bio Clinical Site, Kyiv, Ukraine
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
Phase 2
Completed
- Conditions
- Tenosynovial Giant Cell TumorPigmented Villonodular Synovitis (PVNS)
- Interventions
- Biological: AMB-05X
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- AmMax Bio, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04731675
- Locations
- 🇺🇦
AmMax Bio Clinical Site, Kyiv, Ukraine
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
Phase 1
Completed
- Conditions
- Pancreatic CancerColorectal CancerNon-Small Cell Lung Cancer
- Interventions
- Biological: AMG820 and pembrolizumab
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- AmMax Bio, Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT02713529
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇪🇸Research Site, Madrid, Spain
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
A Study of AMG 820 in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid TumorsCancerOncologyTumorsAdvanced MalignancyOncology Patients
- Interventions
- First Posted Date
- 2011-09-30
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- AmMax Bio, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01444404
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath